• UPDATE : 2019.10.16 수 16:44
상단여백
기사 (전체 76건)
Jardiance reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
(Business Wire/Korea Newswire) New data showed that empagliflozin reduced t...
라인
Takeda Receives Positive CHMP Opinion for ADCETRIS(brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
라인
Fulvestrant Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
--(Business Wire/Korea Newswire) November 15, 2017 -- AstraZeneca today ann...
라인
Cyltezo, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced that th...
라인
Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59th American Society of Hematology Annual Meeting
--(Business Wire/Korea Newswire) November 07, 2017 -- Takeda Pharmaceutical...
라인
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
라인
Efficacy and safety maintained in patients who switched from Humira to biosimilar Cyltezo
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced one-yea...
라인
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis
(Business Wire/Korea Newswire) Boehringer Ingelheim and Dicerna Pharmaceuti...
라인
Strong first half performance with double-digit EPS growth…Takeda Reports First Half FY2017 Results
OSAKA, JAPAN--(Business Wire/Korea Newswire) Takeda Pharmaceutical Company ...
라인
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an...
라인
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (d...
라인
FASLODEX(FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB
AstraZeneca today announced that the Committee for Medicinal Products for H...
라인
European Commission Approves 'Symtuza' for the Treatment of HIV-1 In Adults and Adolescents in Europe
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adu...
라인
Takeda to Feature ALUNBRIG Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
라인
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and ir...
라인
CHMP positive opinion to include RE-CIRCUIT data for atrial fibrillation patients undergoing catheter ablation in Pradaxa Summary of Product Characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European M...
라인
dabigatran etexilate dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement
The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (da...
라인
initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announ...
라인
Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen
Janssen-Cilag International NV (Janssen) today announced that an investigat...
라인
New data to be presented will inform physicians on different aspects of treatment for patients with atrial fibrillation
Boehringer Ingelheim today announced that it will present important new dat...
Back to Top